These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 35145275)

  • 41. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations.
    Beal B; Schutte AE; Neuen BL
    Curr Hypertens Rep; 2023 Dec; 25(12):429-435. PubMed ID: 37948021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ; Day C; Bellary S
    Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
    Giorgino F; Vora J; Fenici P; Solini A
    Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal physiology of glucose handling and therapeutic implications.
    Cherney DZ; Kanbay M; Lovshin JA
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i3-i12. PubMed ID: 32003835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
    Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SGLT2 Inhibitors' Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review.
    Khiali S; Taban-Sadeghi M; Sarbakhsh P; Khezerlouy-Aghdam N; Rezagholizadeh A; Asham H; Entezari-Maleki T
    J Clin Pharmacol; 2023 Dec; 63(12):1307-1323. PubMed ID: 37455561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current Perspectives of the Use of Sodium-Glucose Transport-2 Inhibitors for Patients With Heart Failure and Chronic Kidney Disease.
    Vider E; Sapir R; Mosseri E; Gavioli E
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):247-253. PubMed ID: 34775428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.
    Paolisso P; Bergamaschi L; Cesaro A; Gallinoro E; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Belmonte M; Esposito G; Morici N; Andrea Oreglia J; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Calabrò P; Barbato E; Marfella R; Pizzi C
    Diabetes Res Clin Pract; 2023 Aug; 202():110766. PubMed ID: 37276980
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
    Jhund PS
    Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SGLT2 inhibitors in people with and without T2DM.
    Khunti K
    Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
    [No Abstract]   [Full Text] [Related]  

  • 58. Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications.
    Sise ME; Katz-Agranov N; Strohbehn IA; Harden D; Moreno D; Durbin C; Toribio M; Neilan TG; Zanni MV
    J Acquir Immune Defic Syndr; 2023 Sep; 94(1):53-56. PubMed ID: 37229530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
    Neuen BL; Jardine MJ; Perkovic V
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.